KIORA PHARMACEUTICALS INC — Director's Dealing 2015

Feb 23, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2015-02-19

Reporting Person: HANCOCK THOMAS (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-02-19	Stock Option (right to buy)	$6	A	2276	Acquired	2025-02-19	Common Stock (2276)	Direct

Footnotes

F1: The option became exercisable as to 33% of the shares underlying the option on April 24, 2014 and the remaining balance vests monthly on the first day of each calendar month thereafter.